Treatment of NAFLD with N-Acetylsyctein, Pioglitazon and Metformin

Comparison of the effectivness of N-Acetylsyctein, Pioglitazon and Metformin in the treatment of non alcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201309188308N3

Enrollment

Registered

2015-02-23

Start date

2014-11-18

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Alcoholic Fatty Liver Disease. Nonalcoholic steatohepatitis

Interventions

Intervention 1: Third group: metformin tablets 500 mg every 12 hours for two months. Intervention 2: Second group pioglitazone 30 mg tablets for two months. Intervention 3: First group: N-acetylcystei

Treatment - Drugs

Third group: metformin tablets 500 mg every 12 hours for two months

Second group pioglitazone 30 mg tablets for two months

First group: N-acetylcysteine 600 mg tablets for two months

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1) Elevated liver enzymes > 1.5 times 2) Sonographic diagnosis of NAFLD (Grade 1 and more) Exclusion criteria: 1) Viral hepatitis 2) Alcoholic liver disease 3) Autoimmune liver disease 4) Hepatotoxic drug use in the past 6 month 5) Systemic illness 6) Metabolic liver disease 7) Active drug abuse 8) Pregnancy 9) Diabetes mellitus

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Liver enzymes. Timepoint: two month. Method of measurement: Labratory.	—

Secondary

Measure	Time frame
Grading of Steatosis. Timepoint: two month. Method of measurement: Sonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contact?Dr.Mehdi.Rezvan

University of Medical Sciencesof Hamedan

drmrezvan@gmail.com+98 81 3838 5914

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026